TRAX
First Tracks Biotherapeutics, Inc.
Price Chart
Latest Quote
$18.17
+1.03 (+6.01%)
Current Price
| Previous Close | $17.14 |
| Open | $17.17 |
| Day High | $18.54 |
| Day Low | $17.09 |
| Volume | 725,654 |
Stock Information
| Shares Outstanding | 34.89M |
| Cash Equivalents | $286.46M |
| Net Income | $-169.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $633.99M |
| EPS (TTM) | $-4.71 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $311.60M |
| Income | $-169.38M |
| Book/sh | $7.38 |
| Cash/sh | $8.21 |
| Employees | 104 |
Financial Ratios
| Quick Ratio | 8.65 |
| Current Ratio | 8.74 |
Returns & Margins
Ownership
| Insider Ownership | 6.51% |
| Institutional Ownership | 44.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.79 |
| P/B | 2.46 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $38.12 |
Technical Indicators
| SMA20 | $16.77 |
| SMA50 | $19.00 |
| RSI | 58.23 |
| ATR | 1.7493 |
| Shares Float | 31.08M |
| Short Ratio | 8.69 |
| Rel Volume | 1.44 |
Performance History
| Week | +10.66% |
| Month | +2.14% |
| YTD | -4.37% |
| 10 Years | -4.37% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $18.17 | 734,400 |
| 2026-06-16 | $17.14 | 547,600 |
| 2026-06-15 | $17.88 | 484,300 |
| 2026-06-12 | $17.64 | 415,300 |
| 2026-06-11 | $17.03 | 550,000 |
| 2026-06-10 | $16.42 | 365,400 |
| 2026-06-09 | $15.97 | 391,000 |
| 2026-06-08 | $15.75 | 674,700 |
| 2026-06-05 | $16.60 | 868,800 |
| 2026-06-04 | $18.20 | 536,200 |
| 2026-06-03 | $15.32 | 554,900 |
| 2026-06-02 | $16.14 | 720,300 |
| 2026-06-01 | $18.09 | 854,700 |
| 2026-05-29 | $15.96 | 471,500 |
| 2026-05-28 | $15.82 | 298,200 |
| 2026-05-27 | $16.14 | 336,100 |
| 2026-05-26 | $17.06 | 290,800 |
| 2026-05-22 | $17.18 | 318,500 |
| 2026-05-21 | $16.76 | 307,300 |
| 2026-05-20 | $16.17 | 491,200 |
| 2026-05-19 | $16.66 | 509,000 |
| 2026-05-18 | $17.79 | 365,900 |
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
đ° Latest News
How The Grupo TraxiÃŗn (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets
Simply Wall St. âĸ 2026-05-15T14:18:45Z
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
Insider Monkey âĸ 2026-05-10T23:13:55Z
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares
MT Newswires âĸ 2026-03-27T13:58:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $181,101,000 | $118,461,000 |
| Other Income Expense | $14,000 | $-2,000 |
| Other Non Operating Income Expenses | $14,000 | $-2,000 |
| Net Non Operating Interest Income Expense | $17,382,000 | $12,313,000 |
| Operating Expense | $181,101,000 | $118,461,000 |
| General And Administrative Expense | $28,756,000 | $20,867,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-163,705,000 | $-106,150,000 |
| Net Interest Income | $17,382,000 | $12,313,000 |
| Interest Income | $17,382,000 | $12,313,000 |
| Normalized Income | $-163,705,000 | $-106,150,000 |
| Net Income From Continuing And Discontinued Operation | $-163,705,000 | $-106,150,000 |
| Total Operating Income As Reported | $-181,101,000 | $-118,461,000 |
| Net Income Common Stockholders | $-163,705,000 | $-106,150,000 |
| Net Income | $-163,705,000 | $-106,150,000 |
| Net Income Including Noncontrolling Interests | $-163,705,000 | $-106,150,000 |
| Net Income Continuous Operations | $-163,705,000 | $-106,150,000 |
| Pretax Income | $-163,705,000 | $-106,150,000 |
| Interest Income Non Operating | $17,382,000 | $12,313,000 |
| Operating Income | $-181,101,000 | $-118,461,000 |
| Per Share | ||
| Diluted EPS | - | $-3.05 |
| Basic EPS | - | $-3.05 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-178,704,000 | $-116,085,000 |
| Reconciled Depreciation | $2,397,000 | $2,376,000 |
| EBITDA (Bullshit earnings) | $-178,704,000 | $-116,085,000 |
| EBIT | $-181,101,000 | $-118,461,000 |
| Diluted NI Availto Com Stockholders | $-163,705,000 | $-106,150,000 |
| Research And Development | $152,345,000 | $97,594,000 |
| Selling General And Administration | $28,756,000 | $20,867,000 |
| Other Gand A | $28,756,000 | $20,867,000 |
| Diluted Average Shares | - | $34,748,841 |
| Basic Average Shares | - | $34,748,841 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $391,596,000 | $409,849,000 |
| Total Assets | $441,891,000 | $444,109,000 |
| Total Non Current Assets | $51,958,000 | $45,554,000 |
| Other Non Current Assets | $256,000 | $256,000 |
| Current Assets | $389,933,000 | $398,555,000 |
| Other Current Assets | $4,560,000 | $7,651,000 |
| Prepaid Assets | $4,560,000 | $7,651,000 |
| Cash Cash Equivalents And Short Term Investments | $385,373,000 | $390,904,000 |
| Cash And Cash Equivalents | $123,080,000 | $35,965,000 |
| Debt | ||
| Total Debt | $16,037,000 | $17,814,000 |
| Long Term Debt And Capital Lease Obligation | $14,112,000 | $16,037,000 |
| Current Debt And Capital Lease Obligation | $1,925,000 | $1,777,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $50,295,000 | $34,260,000 |
| Total Non Current Liabilities Net Minority Interest | $14,112,000 | $16,037,000 |
| Current Liabilities | $36,183,000 | $18,223,000 |
| Payables And Accrued Expenses | $26,839,000 | $11,853,000 |
| Payables | $3,785,000 | $2,425,000 |
| Accounts Payable | $3,785,000 | $2,425,000 |
| Equity | ||
| Common Stock Equity | $391,596,000 | $409,849,000 |
| Total Equity Gross Minority Interest | $391,596,000 | $409,849,000 |
| Stockholders Equity | $391,596,000 | $409,849,000 |
| Other Equity Interest | $391,291,000 | $410,646,000 |
| Gains Losses Not Affecting Retained Earnings | $305,000 | $-797,000 |
| Other | ||
| Ordinary Shares Number | $34,748,841 | $34,748,841 |
| Share Issued | $34,748,841 | $34,748,841 |
| Tangible Book Value | $391,596,000 | $409,849,000 |
| Invested Capital | $391,596,000 | $409,849,000 |
| Working Capital | $353,750,000 | $380,332,000 |
| Capital Lease Obligations | $16,037,000 | $17,814,000 |
| Total Capitalization | $391,596,000 | $409,849,000 |
| Capital Stock | $391,291,000 | $410,646,000 |
| Common Stock | $391,291,000 | $410,646,000 |
| Long Term Capital Lease Obligation | $14,112,000 | $16,037,000 |
| Current Capital Lease Obligation | $1,925,000 | $1,777,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,419,000 | $4,593,000 |
| Current Accrued Expenses | $23,054,000 | $9,428,000 |
| Investments And Advances | $35,470,000 | $27,026,000 |
| Net PPE | $16,232,000 | $18,272,000 |
| Accumulated Depreciation | $-6,599,000 | $-6,218,000 |
| Gross PPE | $22,831,000 | $24,490,000 |
| Leases | $203,000 | $203,000 |
| Other Properties | $21,098,000 | $22,647,000 |
| Machinery Furniture Equipment | $1,530,000 | $1,640,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $262,293,000 | $354,939,000 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-126,164,000 | $-93,811,000 |
| Operating Activities | ||
| Operating Cash Flow | $-125,806,000 | $-93,004,000 |
| Cash Flow From Continuing Operating Activities | $-125,806,000 | $-93,004,000 |
| Investing Activities | ||
| Capital Expenditure | $-358,000 | $-807,000 |
| Investing Cash Flow | $95,398,000 | $144,754,000 |
| Cash Flow From Continuing Investing Activities | $95,398,000 | $144,754,000 |
| Financing Activities | ||
| Financing Cash Flow | $117,523,000 | $-87,093,000 |
| Cash Flow From Continuing Financing Activities | $117,523,000 | $-87,093,000 |
| Net Other Financing Charges | $117,523,000 | $-87,093,000 |
| Net Common Stock Issuance | $117,523,000 | $-87,093,000 |
| Other | ||
| End Cash Position | $123,080,000 | $35,965,000 |
| Beginning Cash Position | $35,965,000 | $71,308,000 |
| Changes In Cash | $87,115,000 | $-35,343,000 |
| Net Investment Purchase And Sale | $95,756,000 | $145,561,000 |
| Sale Of Investment | $476,132,000 | $449,480,000 |
| Purchase Of Investment | $-380,376,000 | $-303,919,000 |
| Net PPE Purchase And Sale | $-358,000 | $-807,000 |
| Purchase Of PPE | $-358,000 | $-807,000 |
| Change In Working Capital | $18,988,000 | $2,898,000 |
| Change In Other Current Liabilities | $-1,777,000 | $-1,636,000 |
| Change In Payables And Accrued Expense | $17,813,000 | $8,391,000 |
| Change In Payable | $17,813,000 | $8,391,000 |
| Change In Account Payable | $17,813,000 | $8,391,000 |
| Change In Prepaid Assets | $2,952,000 | $-3,857,000 |
| Stock Based Compensation | $26,827,000 | $18,393,000 |
| Amortization Of Securities | $-10,313,000 | $-10,521,000 |
| Depreciation Amortization Depletion | $2,397,000 | $2,376,000 |
| Depreciation And Amortization | $2,397,000 | $2,376,000 |
| Depreciation | $2,397,000 | $2,376,000 |
| Net Income From Continuing Operations | $-163,705,000 | $-106,150,000 |
Fetched: 2026-06-14